DermTech Announces Closing of Public Offering of Common Stock & Full Exercise of Underwriters’ Option to Purchase Additiona...
January 11 2021 - 4:01PM
Business Wire
DermTech, Inc. (Nasdaq: DMTK) (“DermTech”), a leader in
precision dermatology enabled by a non-invasive skin genomics
platform, announced today the closing of its previously announced
underwritten public offering of 4,872,881 shares of its common
stock, which includes the exercise in full by the underwriters of
their option to purchase up to 635,593 additional shares, at a
price to the public of $29.50 per share. DermTech’s aggregate gross
proceeds from the offering, before deducting underwriting discounts
and commissions and other offering expenses, were $143.7 million.
All of the shares in the offering were sold by DermTech.
Cowen and William Blair acted as joint book-running managers for
the offering. BTIG, Craig-Hallum and Oppenheimer & Co. acted as
lead managers for the offering, and Lake Street Capital Markets
acted as co-manager for the offering.
The offering was made only by means of a written prospectus and
related prospectus supplement forming part of DermTech’s shelf
registration statement on Form S-3 (File No. 333-248642) that was
filed with the Securities and Exchange Commission (the “SEC”) on
September 8, 2020 and declared effective by the SEC on September
17, 2020. The final prospectus supplement and accompanying
prospectus are available at the SEC’s website located at
www.sec.gov. Alternatively, copies may be obtained, from Cowen and
Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by
email at PostSaleManualRequests@broadridge.com or by telephone at
(833) 297-2926, or from William Blair & Company, L.L.C.,
Attention: Prospectus Department, 150 North Riverside Plaza,
Chicago, IL 60606, or by email at prospectus@williamblair.com or by
telephone at 1-800-621-0687.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state or other jurisdiction.
About DermTech:
DermTech is the leading genomics company in dermatology and is
creating a new category of medicine, precision dermatology, enabled
by our non-invasive skin genomics platform. DermTech’s mission is
to transform dermatology with our non-invasive skin genomics
platform, to democratize access to high quality dermatology care,
and to improve the lives of millions. DermTech provides genomic
analysis of skin samples collected non-invasively using an adhesive
patch rather than a scalpel. DermTech markets and develops products
that facilitate the early detection of skin cancers, and is
developing products that assess inflammatory diseases and customize
drug treatments.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210111005950/en/
Sarah Dion VP Marketing sdion@dermtech.com (858) 450-4222
Investor Relations: Caroline Corner, PhD Westwicke, an ICR company
caroline.corner@westwicke.com (415) 202-5678
DermTech (NASDAQ:DMTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
DermTech (NASDAQ:DMTK)
Historical Stock Chart
From Apr 2023 to Apr 2024